← Back to all signals
RESEARCH PAPER ANALYSIS

Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients.

AI interpretation is pending for this paper.

Open original publication →
PMID38958237
JournalInternational journal of cancer
Publication Date2024-07-03
Ingested2026-08-02 12:02 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

A lot of hope for high-risk cancers is being pinned on immunotherapy but the evidence in children is lacking due to the rarity and limited efficacy of single-agent approaches. Here, we aim to assess the effectiveness of multimodal therapy comprising a personalized dendritic cell (DC) vaccine in children with relapsed and/or high-risk solid tumors using the N-of-1 approach in real-world scenario. A total of 160 evaluable events occurred in 48 patients during the 4-year follow-up. Overall survival of the cohort was 7.03 years. Disease control after vaccination was achieved in 53.8% patients. Comparative survival analysis showed the beneficial effect of DC vaccine beyond 2 years from initial diagnosis (HR = 0.53, P = .048) or in patients with disease control (HR = 0.16, P = .00053). A trend for synergistic effect with metronomic cyclophosphamide and/or vinblastine was indicated (HR = 0.60 P = .225). A strong synergistic effect was found for immune check-point inhibitors (ICIs) after priming with the DC vaccine (HR = 0.40, P = .0047). In conclusion, the personalized DC vaccine was an effective component in the multimodal individualized treatment. Personalized DC vaccine was effective in less burdened or more indolent diseases with a favorable safety profile and synergized with metronomic and/or immunomodulating agents.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Comparison of Phenol Application and Endoscopic Pilonidal Sinus Treatment in Pediatric Pilonidal Sinus Disease. Pediatrics international : official journal of the Japan Pediatric Society 63.74 2 Unfinished Business and Experiences of Bereaved Families of Patients with Cancer: A Cross-Sectional Survey. Palliative medicine reports 61.0 3 The 21st International ``Ponte di Legno'' Childhood Acute Lymphoblastic Leukemia Workshop Report: Progress and Emerging Opportunities. Clinical lymphoma, myeloma & leukemia 49.0 4 Acute Leukemia During the First Six Months of Life: A Population-Based Analysis of Survival by Leukemia Type. Clinical lymphoma, myeloma & leukemia 64.12 5 Pediatric orbital solitary fibrous tumor/hemangiopericytoma presenting with isolated eyelid edema: a case report. Frontiers in pediatrics 53.1 6 Malignancies in patients with inborn errors of immunity: insights from 20-years of clinical experience in Qatar. Frontiers in immunology 68.6 7 Precision medicine and parental experience: a longitudinal study of psychosocial responses to germline genomic results in pediatric oncology. Frontiers in medicine 67.36 8 Cytokine-augmented risk stratification for six-month incident nephritis in children with IgA vasculitis. Frontiers in pediatrics 58.5 9 Time-bounded uncertainty in childhood cancer survivorship: a psycho-oncology perspective on result communication. Frontiers in psychology 57.0 10 "From misdiagnosis to precision medicine: strengthening pediatric neuro-oncology care in LMICs toward equitable pLGG outcomes". Frontiers in oncology 75.5 11 Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German-Austrian Expert Opinion Paper. European journal of neurology 66.4 12 Technical Considerations for Robotic Pediatric Lobectomy. Annals of thoracic surgery short reports 54.0 13 Kaposi Sarcoma-Associated Herpesvirus Is Not Detected in Osteosarcoma From KSHV-Endemic African Countries and the Non-Endemic United States Populations. Journal of medical virology 59.5 14 ELISA (Embedding-Linked Interactive Single-cell Agent): an interpretable hybrid generative Artificial Intelligence agent for expression-grounded discovery in single-cell genomics. Briefings in bioinformatics 48.5 15 Thyroid Cancer in the Modern Era: From Molecular Landscape and Multimodal Diagnostics to Integrative Traditional Chinese Medicine-A Comprehensive Review. Cancer management and research 90.6 16 Presumed left atrial myxoma presenting with seizures, massive stroke, and systemic embolization in an adolescent: a case report. International journal of emergency medicine 49.0 17 Ewing's Sarcoma in Adults: A Predictive Nomogram and Survival Analysis of a Cohort of 937 Patients. Journal of surgical oncology 73.92 18 Comments on "Initial Cerebrospinal Fluid Blast Clearance Rate in Pediatric B-Lymphoblastic Leukemia Is Associated With Overall Survival". Journal of pediatric hematology/oncology 49.12 19 Impact of Number of Lymph Nodes Sampled and Density of Positive Nodes on Outcomes Among Over 2000 Patients With Stage I to III Favorable Histology Wilms Tumor Enrolled on AREN03B2: A Children's Oncology Group Renal Tumor Study. Annals of surgery 70.5 20 Prognostic impact of risk organ involvement and metabolic parameters assessed by staging 18F-FDG PET/CT in pediatric Langerhans cell histiocytosis. Nuclear medicine communications 63.3 21 Prognostic value of plasma thymus- and activationregulated chemokine levels after the second cycle of chemotherapy in pediatric Hodgkin lymphoma. Haematologica 55.44 22 Germline lymphoma-predisposing variants: impact on age of cancer diagnosis and survival in pediatric patients. Haematologica 51.12 23 Excess mortality convergence after paediatric allogeneic transplantation: a caveat for the right to be forgotten. Comment on: "Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia". Haematologica 49.5 24 EARLY DISCONTINUATION OF ANTIBIOTICS IN PEDIATRIC PATIENTS WITH LOW- AND HIGH-RISK FEBRILE NEUTROPENIA: A SINGLE-CENTRE EXPERIENCE. Journal of the Pediatric Infectious Diseases Society 68.4 25 Comment on "How I Approach Anxiety in Children and Teens with Cancer". Pediatric blood & cancer 47.5 26 Progressive Tracheal Injury Following Tumor Regression in a Child With T-Cell Lymphoblastic Lymphoma. Pediatric blood & cancer 28.5 27 Very Late Relapse of Acute Myeloid Leukemia With a Rare HNRNPH1::MLLT10 Fusion Following a Pediatric Myeloid Neoplasm: A Successful Venetoclax-Azacitidine Bridge to Hematopoietic Stem Cell Transplantation. Pediatric blood & cancer 49.12 28 Interventions to Reduce Financial Toxicity of Childhood, Adolescent, and Young Adult Cancer Survivors: A Scoping Review. Pediatric blood & cancer 61.32 29 ENCERT: A Multisite Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide, and Etoposide in Relapsed T-Cell Lymphoblastic Leukemia/Lymphoma. Pediatric blood & cancer 87.42 30 Advanced Radiotherapy Across a Multi-Geography Referral Network for Children With Ewing Sarcoma and Rhabdomyosarcoma: Treatment Delivery and Early Outcomes-A Single-Centre Experience. Pediatric blood & cancer 72.88 31 Genomic Characterization of ETV6::RUNX1-Positive Childhood B-ALL in a Chinese Cohort: Novel Fusion Partners, Co-Occurring Mutations, and Risk-Stratifying Biomarkers. Pediatric blood & cancer 59.75 32 Diagnostic Yield of Brain MRI in Pediatric Short Stature: Hypothalamic-Pituitary Lesions and Incidental Findings in Real-World Practice. Clinical endocrinology 67.3
PATIENT-FRIENDLY SUMMARY

Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients.

For education only—not personal medical advice.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic